Latest Pharma Insights
Ionis’s Olezarsen Data Meet Multiple Marks In Blockbuster sHTG Indication
Phase III CORE and CORE2 results presented at the AHA meeting in severe hypertriglyceridemia showed durable triglyceride lowering and reductions in acute pancreatitis across patient subgroups, supporting expansion of Tryngolza (olezarsen) into a second, larger indication.
Scrip - November 8, 2025
Phase III CORE and CORE2 results presented at the AHA meeting in severe hypertriglyceridemia showed durable triglyceride lowering and reductions in acute pancreatitis across patient subgroups, supporting expansion of Tryngolza (olezarsen) into a second, larger indication.
Scrip - November 8, 2025
Amgen’s ‘Stunning’ VESALIUS Results Could Push Repatha Into The Mainstream
Cardiologists know PCSK9 inhibition is a powerful LDL-lowering tool and now Amgen’s VESALIUS data show it may be worth adding to the primary care physician’s toolbox for prevention of high-risk patients’ first major cardiovascular events.
Scrip - November 8, 2025
Cardiologists know PCSK9 inhibition is a powerful LDL-lowering tool and now Amgen’s VESALIUS data show it may be worth adding to the primary care physician’s toolbox for prevention of high-risk patients’ first major cardiovascular events.
Scrip - November 8, 2025
Synchron Secures $200M Series D, Plans New Brain Interface With ‘Potentially More Applications’
Synchron raised $200m in series D funding to support pivotal trials in 2026 as well as commercialization of its Stentrode BCI. It also announced plans for a next-gen high-channel whole-brain interface and a new engineering hub in San Diego.
Medtech Insight - November 8, 2025
Synchron raised $200m in series D funding to support pivotal trials in 2026 as well as commercialization of its Stentrode BCI. It also announced plans for a next-gen high-channel whole-brain interface and a new engineering hub in San Diego.
Medtech Insight - November 8, 2025
Ionis’s Olezarsen Data Meet Multiple Marks In Blockbuster sHTG Indication
Phase III CORE and CORE2 results presented at the AHA meeting in severe hypertriglyceridemia showed durable triglyceride lowering and reductions in acute pancreatitis across patient subgroups, supporting expansion of Tryngolza (olezarsen) into a second, larger indication.
Scrip - November 8, 2025
Phase III CORE and CORE2 results presented at the AHA meeting in severe hypertriglyceridemia showed durable triglyceride lowering and reductions in acute pancreatitis across patient subgroups, supporting expansion of Tryngolza (olezarsen) into a second, larger indication.
Scrip - November 8, 2025
Amgen’s ‘Stunning’ VESALIUS Results Could Push Repatha Into The Mainstream
Cardiologists know PCSK9 inhibition is a powerful LDL-lowering tool and now Amgen’s VESALIUS data show it may be worth adding to the primary care physician’s toolbox for prevention of high-risk patients’ first major cardiovascular events.
Scrip - November 8, 2025
Cardiologists know PCSK9 inhibition is a powerful LDL-lowering tool and now Amgen’s VESALIUS data show it may be worth adding to the primary care physician’s toolbox for prevention of high-risk patients’ first major cardiovascular events.
Scrip - November 8, 2025
Synchron Secures $200M Series D, Plans New Brain Interface With ‘Potentially More Applications’
Synchron raised $200m in series D funding to support pivotal trials in 2026 as well as commercialization of its Stentrode BCI. It also announced plans for a next-gen high-channel whole-brain interface and a new engineering hub in San Diego.
Medtech Insight - November 8, 2025
Synchron raised $200m in series D funding to support pivotal trials in 2026 as well as commercialization of its Stentrode BCI. It also announced plans for a next-gen high-channel whole-brain interface and a new engineering hub in San Diego.
Medtech Insight - November 8, 2025
Perrigo: Morning After Pill ‘Poorly Understood’ By Young Brits Having Unprotected Sex
Lots of young people in the UK are having unprotected sex, but are not using emergency contraception or do not understand very well how it works, according to a recent Perrigo survey.
HBW Insight - November 7, 2025
Lots of young people in the UK are having unprotected sex, but are not using emergency contraception or do not understand very well how it works, according to a recent Perrigo survey.
HBW Insight - November 7, 2025
Karo To Grow Lamisil In Europe With ‘Next Generation’ Fungal Nail Treatment
Karo will take on responsibility for the marketing, distribution and sales of Moberg’s topical onychomycosis treatment, MOB-15, under the Lamisil brand in 19 European countries.
HBW Insight - November 7, 2025
Karo will take on responsibility for the marketing, distribution and sales of Moberg’s topical onychomycosis treatment, MOB-15, under the Lamisil brand in 19 European countries.
HBW Insight - November 7, 2025
Brits Becoming More Deficient In Key Nutrients, Pointing To Need For Supplementation
Brits are consuming insufficient amounts of vitamin D, riboflavin, folate, iron, calcium, potassium, iodine, selenium and omega 3, according to a recently published study. Consumer health companies can help by providing affordable supplements with easy to understand health claims.
HBW Insight - November 7, 2025
Brits are consuming insufficient amounts of vitamin D, riboflavin, folate, iron, calcium, potassium, iodine, selenium and omega 3, according to a recently published study. Consumer health companies can help by providing affordable supplements with easy to understand health claims.
HBW Insight - November 7, 2025
Coty CEO Talks Outlook For Fragrance Business Post-Gucci, Strategic Review Of Cosmetics
Coty plans to maximize Gucci beauty’s performance through the end of the licensing contract that ends in 2028, while accelerating growth in newer and higher-potential brands to offset the financial loss.
HBW Insight - November 7, 2025
Coty plans to maximize Gucci beauty’s performance through the end of the licensing contract that ends in 2028, while accelerating growth in newer and higher-potential brands to offset the financial loss.
HBW Insight - November 7, 2025
‘We Will Be Everywhere’: Amneal On Biosimilar Vertical Integration And ‘Dead’ Licensing Deals
Amneal continues to see biosimilars as an attractive but competitive space, with vertical integration in the US market being a key to its success.
Generics Bulletin - November 7, 2025
Amneal continues to see biosimilars as an attractive but competitive space, with vertical integration in the US market being a key to its success.
Generics Bulletin - November 7, 2025
Outlook Therapeutics Takes Another Shot At US Approval For Ophthalmic Bevacizumab
Outlook Therapeutics believes its revised filing addresses the FDA’s sole remaining concern from an August complete response letter, setting up a potential mid-2026 decision on its wet AMD therapy.
Generics Bulletin - November 7, 2025
Outlook Therapeutics believes its revised filing addresses the FDA’s sole remaining concern from an August complete response letter, setting up a potential mid-2026 decision on its wet AMD therapy.
Generics Bulletin - November 7, 2025
Viatris Nears Completion Of Company-Wide Strategic Review
Having spent the past several years divesting non-core assets and strengthening its balance sheet, Viatris is now focused on improving efficiency and profitability across its global operations.
Generics Bulletin - November 7, 2025
Having spent the past several years divesting non-core assets and strengthening its balance sheet, Viatris is now focused on improving efficiency and profitability across its global operations.
Generics Bulletin - November 7, 2025
Teva Calls Off TAPI Deal, Eyes New Sale As Market Conditions Improve
Teva has ended exclusive talks to sell its active pharmaceutical ingredients arm after failing to reach terms that aligned with its strategic and shareholder interests, but plans to relaunch the process as shifting geopolitical and market conditions renew buyer interest.
Generics Bulletin - November 7, 2025
Teva has ended exclusive talks to sell its active pharmaceutical ingredients arm after failing to reach terms that aligned with its strategic and shareholder interests, but plans to relaunch the process as shifting geopolitical and market conditions renew buyer interest.
Generics Bulletin - November 7, 2025
Astellas’s New Head Of Innovation Lab Sets Fresh Direction For External R&D
Launched in April 2025, Astellas’s Innovation Lab unites fragmented research units under Morten Sogaard to pursue focused indications, a dual-track R&D strategy and tailored partnerships that balance innovation, risk and collaboration.
In Vivo - November 6, 2025
Launched in April 2025, Astellas’s Innovation Lab unites fragmented research units under Morten Sogaard to pursue focused indications, a dual-track R&D strategy and tailored partnerships that balance innovation, risk and collaboration.
In Vivo - November 6, 2025
OS Therapies Eyes Mid 2026 Launch After Breakthrough Osteosarcoma Vaccine Results
New York biotech OS Therapies reported 75% two-year survival in an osteosarcoma trial of its immunotherapy, OST-HER2. Leadership is targeting early 2026 approvals across three continents for what is the first new osteosarcoma treatment in 40 years.
In Vivo - November 6, 2025
New York biotech OS Therapies reported 75% two-year survival in an osteosarcoma trial of its immunotherapy, OST-HER2. Leadership is targeting early 2026 approvals across three continents for what is the first new osteosarcoma treatment in 40 years.
In Vivo - November 6, 2025